Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cangrelor’s Approval Prospects: FDA Reviewers Say Yes, Team Leader Says No

This article was originally published in The Pink Sheet Daily

Executive Summary

As The Medicines Co.’s anticlotting drug heads to the Cardiovascular and Renal Drugs Advisory Committee, questions about comparator dosing and timing and the severity of bleeding events will be on the agenda.


Related Content

Cangrelor’s Second Advisory Committee Could Be The Charm
FDA’s Cangrelor “Complete Response” Leaves Room For Approval Without New Trial
TMC Still Optimistic About Cangrelor Approval Despite Negative Opinion
Cangrelor Can’t Escape Its Past At FDA Advisory Committee
Novartis’ Serelaxin Is Early Victim Of East Coast Snow Storm
Avandia Review Endorsement Aided By Good Data, Cultural Shift On Safety
The Medicines Co.’s Cangrelor’s Full CHAMPION PHOENIX Results Bode Well For Filing
Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge
Is TMS' Cangrelor A CHAMPION After All? "Noise On The Line" Confounded Endpoint Data, CEO Says
Can The Medicines Company Rebound From A Phase III Blow?


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts